Several brokerages have updated their recommendations and price targets on shares of Ligand Pharmaceuticals (NASDAQ: LGND) in the last few weeks:
- 11/11/2026 – Ligand Pharmaceuticals had its price target raised by Barclays from $345.00 to $350.00. They now have an “overweight” rating on the stock.
- 11/5/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup from $397.00 to $402.00. They now have a “buy” rating on the stock.
- 11/2/2026 – Ligand Pharmaceuticals was downgraded by Weiss Ratings from “buy (b)” to “hold (c)”.
- 10/30/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $345.00 to $357.00. They now have an “outperform” rating on the stock.
- 9/25/2026 – Ligand Pharmaceuticals is now covered by Barclays. They set an “overweight” rating and a $345.00 price target on the stock.
- 9/24/2026 – Ligand Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $358.00 price target on the stock.
- 9/23/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup from $390.00 to $397.00. They now have a “buy” rating on the stock.
- 9/21/2026 – Ligand Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
Ligand Pharmaceuticals Stock Performance
Shares of LGND traded up $2.88 during mid-day trading on Wednesday, hitting $296.69. 26,556 shares of the company’s stock were exchanged, compared to its average volume of 263,004. The business’s 50 day moving average is $302.13 and its two-hundred day moving average is $259.07. The company has a current ratio of 1.22, a quick ratio of 1.19 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $5.93 billion, a P/E ratio of 132.45, a P/E/G ratio of 5.27 and a beta of 1.16. Ligand Pharmaceuticals Incorporated has a fifty-two week low of $175.89 and a fifty-two week high of $326.63.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.34. The firm had revenue of $78.75 million for the quarter, compared to analyst estimates of $77.00 million. Ligand Pharmaceuticals had a return on equity of 5.22% and a net margin of 20.27%. Ligand Pharmaceuticals’s quarterly revenue was down 31.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.09 earnings per share. On average, equities analysts expect that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.
Insiders Place Their Bets
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Featured Stories
- Five stocks we like better than Ligand Pharmaceuticals
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.
